Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. - Wikidata - awgldk - TriplyDB

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

http://www.wikidata.org/entity/Q41896006

about

Cardio-oncology: Concepts and practice Dual Role of ROS as Signal and Stress Agents: Iron Tips the Balance in favor of Toxic Effects Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment High-Copy Overexpression Screening Reveals PDR5 as the Main Doxorubicin Resistance Gene in Yeast A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling Extracellular control of intracellular drug release for enhanced safety of anti-cancer chemotherapy Cancer drug related cardiotoxicity during breast cancer treatment.Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity.Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity Increased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury.Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.Transcriptome-wide co-expression analysis identifies LRRC2 as a novel mediator of mitochondrial and cardiac function.Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.Drug-induced mitochondrial dysfunction and cardiotoxicity.Potential Roles of Kleinhovia hospita L. Leaf Extract in Reducing Doxorubicin Acute Hepatic, Cardiac and Renal Toxicities in Rats Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.Reduction in mitochondrial iron alleviates cardiac damage during injury Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.Heme oxygenase-1 regulates mitochondrial quality control in the heart.Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.Therapeutic targeting of autophagy in cardiovascular disease.Photodynamic Therapy Induced Enhancement of Tumor Vasculature Permeability Using an Upconversion Nanoconstruct for Improved Intratumoral Nanoparticle Delivery in Deep Tissues A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway.Doxorubicin Regulates Autophagy Signals via Accumulation of Cytosolic Ca2+ in Human Cardiac Progenitor Cells.Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice.

P2860

Q26750878-11E321D5-BDE9-4F8F-BAF3-6C03116F0B54 Q26752455-75F52CFE-EADE-4374-A9F7-AC6F40380320 Q27004011-B17C0A33-BF25-45FD-A22E-F235A0B59366 Q28072058-AE3ECE1D-B9B6-4336-9DD3-ECF891968C87 Q28391344-6887E3CD-EAEB-4588-A001-27BB1369D875 Q28551675-EA52DBCD-F7D2-4B00-9058-372128204398 Q28553631-74ECF95C-6E50-44F4-B29D-F1343E2F4577 Q28580570-556319D5-3EE3-40BA-9412-A6A690F085C9 Q28829328-AF7077F6-CB9A-4BA0-97CD-6139A9D3AA21 Q30251498-07C7EC88-77C6-4CF3-A229-A32547EC6756 Q30628082-AAA9F595-B119-483D-AA37-81CA31DBB613 Q33900003-CF12D43D-0004-4218-AC19-0495969F826B Q33985016-86FD2F0B-FF8D-494E-85A5-4A41BE1F7035 Q35296244-026909C9-A173-4AF3-BAF2-A408D4F13E0E Q35531218-A393677C-384D-481E-AE5C-99E2190CFB40 Q35707221-045CCF68-7BB5-44E1-810B-E6E1EFA63CEF Q35870483-98A8802C-0E5F-4797-9341-2CFA1E950E33 Q35996034-8B875AC3-7DEC-4EDF-8A7A-B28FEEB35174 Q35999766-D602E2E6-2734-42F8-82E0-0FB1E53F78C9 Q36141698-9DAB6E68-B099-4C18-9070-6256840E63DB Q36149227-AF0FEC96-7E1F-440A-B153-8B12E19D5F23 Q36245459-7567F62E-3D67-4399-88CA-109BE39D45D4 Q36269609-E37CF17B-025F-40A0-B061-96963507ED62 Q36296724-95771E96-777A-4DCC-9A2F-E4F583DF826F Q36339445-3FE50DF8-B68A-436B-B91A-023F2259B963 Q36379496-BDEA276D-A64C-427C-A4F9-28694B423A3B Q36559677-EC25E106-AF24-47BD-A82F-889BF3D779C4 Q36636071-A76F8260-5E8E-4AF8-B33E-CAE87F96F714 Q36649653-7C9E0BA2-2C9A-4850-9F83-A965FB452341 Q36819774-E334E94E-3564-4816-829E-B0FCC959D05C Q36864827-7CA6F359-B811-41F2-A2CA-C1A543E17902 Q36869450-BFA6A4C6-4DB4-4AD3-924E-047460C4196E Q36902292-C7C5178A-18FB-4304-A98A-7625B25CC596 Q36913719-D35553EA-7CF9-407D-912E-627E57EF3DFA Q36970360-B97AA718-B4FF-4400-A333-0F1B7C0B65CD Q37204002-53BD85E5-6ED4-48DF-A56C-7B7DAEEFC9BC Q37286660-E6EE6C78-ED1F-4E14-8FB0-A4545663A4F3 Q37377381-925D4D82-B960-4BE2-8474-3C957E5E46C7 Q37378179-4EFC241E-AEE5-4433-8CE8-2462BFBC2790 Q37392811-BE6C6B97-EDD9-46AE-9079-BB2E3CF84996

P2860

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

http://www.wikidata.org/entity/Q41896006

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

@en

type

label

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

@en

prefLabel

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

@en

P1433

Q41896006-94C36D9E-0FD9-42F3-940E-7A6B49CF0C14

P1476

Q41896006-748BF50E-2361-4B1F-86DD-A159A2496608

P2093

Q41896006-311329E0-4B70-4372-92DD-AFB4E16993DA

Q41896006-402ED16D-24E8-4FE8-AE5B-EBDEB0E72E6C

Q41896006-5BD6B25D-ED7F-4667-8024-3DA22E1C399A

Q41896006-612FB26A-0D0F-49C3-8993-72AF981D670A

Q41896006-86F7422A-19C1-49F3-8560-FCCB650759C3

Q41896006-8E148905-F858-461C-A905-16457A3DACDA

Q41896006-B4C19BF4-1B7C-4865-8909-F9B1616A250B

Q41896006-B967031D-DA3B-49A5-A2D6-DE0973997DDB

Q41896006-D681C6F8-5F32-4C12-82BD-D76A31D606C2

P2860

Q41896006-073475FB-B7AA-4246-99EB-C9791799A950

Q41896006-2176423D-50CC-45CF-BE0C-8D121AB9B1EA

Q41896006-2681C85D-9C7B-4D7C-B825-F83626AFE8BF

Q41896006-2AE5893F-2DBA-48E6-AC50-97EEB7585CA1

Q41896006-39C3829D-348A-4C0F-911A-919589EEE8A0

Q41896006-3C386AC8-F919-4344-817B-92D3ABFFDCAA

Q41896006-3C5F425F-7063-4CD1-BDF1-D5F7CA10B85B

Q41896006-41E2C8D3-5121-429F-A61C-D9A6C10A20BE

Q41896006-42FA4303-3030-41D4-89BA-DA0D153457AB

Q41896006-45A5CA29-95D4-42F7-83D4-F60BE0F54D8D

P304

Q41896006-CE7BCF07-0CB0-4808-9BBA-85459E8711B4

P31

Q41896006-320C14EF-73C7-47E6-9BBD-5E35BDCD0963

P356

Q41896006-365A130F-9E17-4513-97AF-2EC8200ADFBA

P407

Q41896006-1D93566A-4710-46D1-B5C7-39B419A62F3F

P433

Q41896006-98CC71A5-2FA6-4994-AF8F-6089279DAB61

P478

Q41896006-17F420C2-DD23-4141-8BD2-67A54F992FE0

P577

Q41896006-DE0D1E04-C1A5-4C86-AA47-B7B379C632E3

P698

Q41896006-CC339DC5-7B51-48E6-9E84-3A43EBE2FBF0

P932

Q41896006-A261437C-6BE3-48B0-9B53-8E901996FC38

P356

P1433

Journal of Clinical Investigation

P1476

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

@en

P2093

Arineh Khechaduri

http://www.w3.org/2001/XMLSchema#string

Hossein Ardehali

http://www.w3.org/2001/XMLSchema#string

Marina Bayeva

http://www.w3.org/2001/XMLSchema#string

Mohsen Ghanefar

http://www.w3.org/2001/XMLSchema#string

R Kannan Mutharasan

http://www.w3.org/2001/XMLSchema#string

Rongxue Wu

http://www.w3.org/2001/XMLSchema#string

Sathyamangla V Naga Prasad

http://www.w3.org/2001/XMLSchema#string

Tejaswitha Jairaj Naik

http://www.w3.org/2001/XMLSchema#string

Yoshihiko Ichikawa

http://www.w3.org/2001/XMLSchema#string

P2860

The role of iron in doxorubicin-induced cardiomyopathy.

Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor.

The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.

Assessment of chelatable mitochondrial iron by using mitochondrion-selective fluorescent iron indicators with different iron-binding affinities.

Update on iron chelators in thalassemia.

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

Anthracyclines: selected new developments.

P304

617-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI72931

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24382354

http://www.w3.org/2001/XMLSchema#string

P932

3904631

http://www.w3.org/2001/XMLSchema#string